Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (619)	12/2/2003 8:24:10 PM
From: Biomaven	Read Replies (1) \| Respond to of 897

so my concern is why 9006 is active for RCC and not for CRC Well RCC is actually fairly unique among cancers in that it is frequently associated (about 50% of cases) with inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene. This causes HIF stabilization which in turn has a myriad of other consequences (like VEGF over-production). I have no idea whether this pathway might interact with 9006 in any way - I'm just pointing out that RCC is different enough to make it plausible that something can work for RCC but not for other cancers. Peter